Trial · NCT00391872
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| PRIMARY | Participants With Any Major Bleeding Event | First dosing up to 12 months | The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug | Participants | NUMBER |
| SECONDARY | Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization | Randomization up to 12 months | The subgroup of patients with intent for invasive management at randomization | Participants | NUMBER |
| SECONDARY | Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events. | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With MI Event | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With Death From Vascular Causes | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With Stroke | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With Death From Any Cause | Randomization up to 12 months | The population was the full analysis set, which included all randomized patients | Participants | NUMBER |
| SECONDARY | Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding | First dosing up to 12 months | The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug | Participants | NUMBER |
| SECONDARY | Participants With Major or Minor Bleeding | First dosing up to 12 months | The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug | Participants | NUMBER |
| SECONDARY | Participants With Non-procedural Major Bleeding | First dosing up to 12 months | The population was the safety analysis set, which included all randomized patients who took at least one dose of study drug | Participants | NUMBER |
| SECONDARY | Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding | First dosing up to 12 months | Population is all patients who underwent CABG surgery within 7 days of last dose of active study medication. | Participants | NUMBER |
| SECONDARY | Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding | First dosing up to 12 months | Population is all patients who underwent CABG surgery within 7 days of last dose of active study medication. | Participants | NUMBER |
| SECONDARY | Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization | 1-week period following randomization | Participants with Holter data in the week after Randomization | Participants | NUMBER |
| SECONDARY | Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization | 1-week period following randomization | Patients who were monitored for one week following randomization (and for one week one month later). | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00391872/outcomes